Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTO-300 Open-label Study in Major Depressive Disorder
NCT05118750Phase 2Completed
- Sponsor
- Alto Neuroscience
- Start
- Dec 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of agomelatine in major depressive disorder (MDD), sponsored by Alto Neuroscience. Primary endpoints: Montgomery-Åsberg Depression Rating Scale at 8 weeks, Clinical Global Impression - Severity at 8 weeks and 1 more. Started Dec 2021; status: completed.
02
Drugs
agomelatine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05118750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05118750.